Revenue
No reported data
LB PHARMACEUTICALS INC (LBRX)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | $16.7M | $51.2M |
| Operating expenses | $30.4M | $64.8M |
| Net income | −$25.2M | −$63.1M |
| Basic EPSper diluted share | -$3.13 | -$176.15 |
| Diluted EPSper diluted share | -$3.13 | -$176.15 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 6, 2026Form 4 | KROIN DAVID +3TenPercentOwner | BuyPre-Funded Warrants (Right to Buy) · derivative · indirect | 93.9K | $21.17 | $1.99M | 93.9K |
| Feb 6, 2026Form 4 | KROIN DAVID +3TenPercentOwner | BuyPre-Funded Warrants (Right to Buy) · derivative | 378.4K | $21.17 | $8.01M | 378.4K |
| Sep 12, 2025Form 4 | Deep Track Capital, LP +2TenPercentOwner | BuyCommon Stock · indirect | 666.7K | $15.00 | $10.00M | 666.7K |
| Sep 12, 2025Form 4 | Deep Track Capital, LP +2TenPercentOwner | BuyCommon Stock | 2.00M | $15.00 | $30.00M | 2.69M |
| Sep 12, 2025Form 4 | Pontifax Management 4 G.P. (2015) Ltd.TenPercentOwner | BuyCommon Stock · indirect | 1.00M | $15.00 | $15.00M | 1.41M |